Role of FGF23 in Pediatric Hypercalciuria.

Maria Goretti Moreira Guimarães Penido
Marcelo de Sousa Tavares
Uri S. Alon

Children's Mercy Hospital

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Part of the Nephrology Commons, Pediatrics Commons, and the Reproductive and Urinary Physiology Commons

Recommended Citation
Moreira Guimarães Penido, M., de Sousa Tavares, M., Alon, U. S. Role of FGF23 in Pediatric Hypercalciuria. Biomed Res Int 2017, 3781525-3781525 (2017).

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Clinical Study
Role of FGF23 in Pediatric Hypercalciuria

Maria Goretti Moreira Guimaraes Penido,1,2 Marcelo de Sousa Tavares,1,2 and Uri Saggie Alon3

1Pediatric Nephrology Unit, Clinics Hospital, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
2Pediatric Nephrology Unit, The Nephrology Center, Santa Casa de Belo Horizonte Hospital, Belo Horizonte, MG, Brazil
3Bone and Mineral Disorders Clinic, Section of Pediatric Nephrology, Children’s Mercy Hospital and Clinics, University of Missouri at Kansas City, Kansas City, MO, USA

Correspondence should be addressed to Maria Goretti Moreira Guimaraes Penido; mariagoretipenido@yahoo.com.br

Received 14 July 2017; Revised 26 September 2017; Accepted 22 October 2017; Published 31 December 2017

Academic Editor: Peyman Bjorklund

Copyright © 2017 Maria Goretti Moreira Guimaraes Penido et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. This study explored the possible role of FGF23 in pediatric hypercalciuria. Methods. Plasma FGF23 was measured in 29 controls and 58 children and adolescents with hypercalciuria: 24 before treatment (Pre-Treated) and 34 after 6 months of treatment (Treated). Hypercalciuric patients also measured serum PTH hormone, 25(OH) vitamin D, phosphate, calcium, creatinine, and 24 h urine calcium, phosphate, and creatinine. Results. There were no differences in age, gender, ethnicity, or body mass index either between controls and patients, or between Pre-Treated and Treated patients. Median plasma FGF23 in controls was 72 compared with all patients, 58 RU/mL (p = 0.0019). However, whereas FGF23 in Pre-Treated patients, 73 RU/mL, was not different from controls, in Treated patients it was 50 RU/mL, significantly lower than in both controls (p < 0.0001) and Pre-Treated patients (p = 0.02). In all patients, there was a correlation between FGF23 and urinary calcium (r = 0.325; p = 0.0014). Treated patients had significantly lower urinary calcium (p < 0.0001), higher TP/GFR (p < 0.001), and higher serum phosphate (p = 0.007) versus Pre-Treated patients. Conclusions. Pharmacological treatment of hypercalciuric patients resulted in significantly lower urinary calcium excretion, lower serum FGF23, and elevated TP/GFR and serum phosphate concentration, without significant changes in PTH. Further studies are indicated. This trial is registered with Clinical Registration Number RBR8W27X5.

1. Introduction

Hypercalciuria is the most common metabolic condition associated with pediatric urolithiasis and some patients demonstrate reduction in bone mass [1–4]. Various mechanisms have been proposed to explain the generalized dysregulation of calcium homeostasis in hypercalciuria, including decreased renal calcium reabsorption, increased gut calcium absorption, and increased bone resorption, or any combination of the above, due to either genetic or environmental effects [5–10].

Studies of adult hypercalciuric stone formers have provided evidence that some of them have significantly lower threshold of tubular reabsorption of phosphate (TP/GFR) and serum phosphorus levels than normal individuals, in the face of normal parathyroid hormone levels [5, 11, 12]. The hypophosphatemia stimulates 1,25(OH)2 vitamin D production and consequently hypercalciuria. However, the cause for the altered tubular phosphate reabsorption is not known. It was suggested that variations in the klotho-FGF23 axis could mediate alterations in phosphate handling by the kidney and thus play a role in hypercalciuria, and indeed a few studies in adult calcium stone formers reported higher fibroblast growth factor 23 (FGF23) levels [5, 13, 14]. On the other hand, a recent study could not implicate FGF23 in the bone alterations seen in these patients [15].

Based on these observations, the aim of this study was to explore the possible role of FGF23 in children with hypercalciuria.

2. Materials and Methods

We performed a cross-sectional study on 58 children, adolescents, and young adults (0 to 24 years) with hypercalciuria and 29 healthy controls (0 to 24 years). Inclusion criteria
Treated group) and 34 patients were evaluated after 6 months.

Kruskal-Wallis test, ANOVA. Standard laboratory methods. Plasma FGF23 concentrations in urine, 25(OH)D, and intact PTH was conducted using different than in controls, that of Treated patients, 50 RU/mL, was statistically lower than 72 RU/mL (56–210) in controls (7.00–368), was significantly lower than in both, controls (p < 0.0001) and Pre-Treated patients (p < 0.02).

Blood and urine data from Pre-Treated and Treated hypercalciuric patients are shown in Table 3. There were no differences in the incidence of urolithiasis between the Pre-Treated and Treated patients. As shown in Table 2, the median value of FGF23 in all hypercalciuric patients, 58 RU/mL (7–368), was statistically lower than 72 RU/mL (56–210) in controls (p = 0.0019).

Further analysis showed that whereas the median value of FGF23 in Pre-Treated patients, 73 RU/mL (32–190), was not different than in controls, that of Treated patients, 50 RU/mL (700–368), was significantly lower than in both, controls (p = 0.0001) and Pre-Treated patients (p < 0.02).

### Table 1: Demographic data of hypercalciuric (H) patients, controls, and Pre-Treated and Treated patients with hypercalciuria.

| Parameters     | H patients N = 58 | Controls N = 29 | P    | Pre-Treated N = 24 | Treated N = 34 | P    |
|----------------|-------------------|-----------------|------|-------------------|----------------|------|
| Age (yr)       | 16.3 (6.3–24.8)   | 16.7 (2.0–24.7) | 0.655| 16.9 (7.6–24.8)   | 15.7 (6.3–23.7) | 0.33 |
| Male (n/%)     | 35/60.5           | 20/66.5         | 0.561| 14/58.5           | 21/62          | 0.79 |
| BMI Z-score    | −0.19 ± 1.26      | −0.35 ± 1.48    | 0.688| −0.02 ± 1.24      | −0.29 ± 1.29   | 0.49 |
| White skin color (n/%) | 38/65.5 | 17/57         | 13/54| 23/67.5           | 23/67.5        | 0.89 |
| Urolithiasis (Y/%) | 44/76     | 0/0             | -    | 18/75             | 26/76.5        | 0.89 |

Data are median (25th and 75th percentiles), mean ± SD, or percentage (number); Y: yes; tests: two-tailed t-test, Wilcoxon rank sum test (two-sided), or Kruskal-Wallis test, ANOVA.

for hypercalciuric patients were urinary calcium excretion ≥ 4 mg/kg/24 h, normocalcemia, and diurnal and nocturnal continent. The control group consisted of sex- and age-matched healthy subjects from our Pediatric Primary Care Center. Health status was determined through the subjects’ medical history and either a parental report or self-report and clinical examination. In all participants, exclusion criteria included nephrocalcinosis, chronic immobilization, hypercalcemia, history of malignancy, excessive oral ingestion of calcium or vitamin D, hyperuricemia, long-term steroid treatment, history of other drug use with possible actions on calcium and phosphorus metabolism during the preceding 2 years, and concurrent conditions associated with metabolic bone disease or renal tubular defects. Of the hypercalciuric patients, 24 were evaluated while receiving no treatment (Pre-Treated group) and 34 patients were evaluated after 6 months of treatment (Treated group). The latter were treated with hydrochlorothiazide 0.5–1.0 mg/Kg/day. Thiazide treatment was initiated when there were low bone mineral density and/or fractures, and no improvement of calcium levels and symptoms was obtained with the initial approach (dietary modification with high fluid intake, low sodium, and the RDA of protein and calcium) [16].

All hypercalciuric patients were asked to continue their daily routine in terms of diet, physical activities, and sun exposure during the blood and urine sample collections. A 24-hour urine sample collected at home and an overnight fasting venous blood sample were obtained at the hospital laboratory. Collection accuracy was verified by urine creatinine excretion rate [17]. The urine sample was analyzed for volume, creatinine, calcium, and phosphate. The blood sample was analyzed for creatinine, calcium, phosphorus, parathyroid hormone (PTH), 25(OH) vitamin D [25(OH)D], and FGF23. Clinical data included age at diagnosis, gender, ethnicity, body mass index (BMI), and history of urolithiasis. In the healthy controls, a blood sample for FGF23 was obtained in all 29. In 16 of them, 24-hour urine calcium, phosphate, and creatinine were analyzed as part of their evaluation for voiding dysfunction.

Analysis of blood and urine phosphate, calcium, creatinine, 25(OH)D, and intact PTH was conducted using standard laboratory methods. Plasma FGF23 concentrations were assessed using a C-terminal assay-ELISA (Immutopics International, San Clemente, CA, USA).

Statistical analysis was performed with SPSS 20 version 18.0 (SPSS, Chicago, IL) software for Windows. The normality of data distribution was assessed using Shapiro-Wilk’s test. Accordingly, descriptive data are expressed as mean ± SD or median (25th and 75th percentiles). Differences between groups were analyzed using two-tailed t-test for unpaired samples when normality conditions were fulfilled and the Wilcoxon rank sum test (two-sided) or Kruskal-Wallis test when they were not. ANOVA was applied for comparisons between three or more groups. Correlations between blood and urinary biochemical parameters were assessed by Spearman correlation test. The level of significance was set up as p < 0.05.

The study was approved by the institutional review board of the Clinics Hospital of the Federal University of Minas Gerais, Brazil (ETIC0479.0.203.000-10, December 01, 2010), and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. The participants and/or their guardians signed informed consent forms.

### 3. Results

Demographic and clinical data of the controls, patients, and their subgroups are shown in Table 1. There were no differences in age, gender, BMI Z-score, or ethnicity between controls and all hypercalciuric patients, or between the Pre-Treated and Treated patients. There was no difference in the incidence of urolithiasis between the Pre-Treated and Treated patients.
Table 2: FGF23 (RU/mL) of controls, hypercalciuric (H) patients, and Pre-Treated and Treated patients with hypercalciuria.

|                      | Median (min–max) |
|----------------------|------------------|
| Controls (n = 29)    | 72.0 (56.0–210.0) |
| H patients (n = 58)  | 58.0 (7.0–368.0)  |
| Pre-Treated (n = 24) | 73.0 (32.0–190.0) |
| Treated (n = 34)     | 50.0 (7.0–368.0)  |

* $p = 0.009$; † $p = 0.02$; ‡ $p < 0.0001$; ♠ $p = 0.26$; test: Wilcoxon rank sum test (two-sided).

Table 3: Blood and urine biochemical parameters in Pre-Treated and Treated patients with hypercalciuria (mean ± SD).

|                      | Pre-Treated | Treated | $p$  |
|----------------------|------------|---------|------|
| Blood                |            |         |      |
| Creatinine (mg/dl)   | 0.74 ± 0.04| 0.67 ± 0.03| 0.22 |
| Calcium (mg/dl)      | 9.59 ± 0.50| 9.70 ± 0.46| 0.35 |
| Phosphate (mg/dl)    | 4.01 ± 0.60| 4.44 ± 0.49| 0.007|
| PTH (pg/ml)          | 29.94 ± 12.25| 25.90 ± 11.21| 0.28 |
| 25(OH)D (ng/ml)      | 28.71 ± 6.25| 32.32 ± 7.86| 0.11 |
| 24-hour urine        |            |         |      |
| Creatinine (mg/kg)   | 21.9 ± 5.1| 20.1 ± 3.3| 0.24 |
| Calcium (mg/kg)      | 5.63 ± 1.21| 2.51 ± 0.71| <0.001|
| TP/GFR               | 3.42 ± 0.15| 3.97 ± 0.10| 0.001|

Test: Wilcoxon scores and Student’s t-test; TP/GFR: phosphate tubular reabsorption by glomerular filtration rate; 25(OH)D: 25OH vitamin D; PTH: parathyroid hormone.

Our hypercalciuric patients demonstrated a positive correlation between 24-hour urinary calcium and serum FGF23 (Figure 1). However, the current study cannot indicate direct cause and effect relationship between the two. Repeat observations in adult hypercalciuric stone formers showed elevated serum 1,25(OH)2D3 concentration [14, 20–22]. Furthermore, the blood FGF23 levels in hypercalciuric patients remains unknown. Considering that FGF23 is an osteocyte-derived hormone, it is possible that higher levels in stone formers could be a marker of abnormal bone physiology. However, Barcellos Menon et al. [15] recently showed that FGF23 expression in osteocytes from hypercalciuric patients was not different from controls and did not correlate with histomorphometric parameters. On the
other hand, these researchers found that bone resorption in these patients could be implicated on 1,25(OH)_{2}D with no correlation with serum PTH [15]. Similarly, the TP/GFR and serum phosphate decreased in the face of equal mean values of PTH, thus, more likely implicating FGF23 (Table 3).

We therefore propose that different or additional mechanisms are involved in hypercalciuria including environmental ones and in particular the effect of nutrition [25]. It has recently been shown that the use of the DASH diet in hypertensive adults results in decreased incidence in urolithiasis [26]. Similar changes were observed in children; namely, decreased dietary intake of sodium on one hand and increase in potassium intake on the other led to a decrease in calcium and stone formation [7–9].

Following anticalciuric treatment, the urine calcium excretion in our patients normalized to the level of healthy controls (Table 3). With that, serum FGF23 decreased and, as expected, both TP/GFR and serum phosphate increased. It thus seems that, with improved calcium retention, a series of unknown events took place resulting in lower plasma FGF23 concentration. As discussed earlier, the change could have been mediated by decrease in serum 1,25(OH)_{2}D_{3} concentration or activity on the bone [15, 27].

Our study has some limitations. Unfortunately due to budgetary constraints, serum 1,25(OH)_{2}D_{3} concentration was not measured. Changes in its level before and following anticalciuric treatment may have served as the missing link in explaining the phenomena observed. Availability of blood and urine data in the control group may have disclosed discrepancies compared with the findings observed in the hypercalciuric patients. The lack of any data on 1,25(OH)_{2}D_{3} levels is a weakness in our study as well as the lack of serum PTH, creatinine, calcium, and phosphate values in controls. Nevertheless, we believe that the aforementioned limitations do not interfere with the observations made in this study of the likelihood of lack of direct role of FGF23 in pediatric hypercalciuria on one hand and the changes observed in its metabolism once pharmacologic anticalciuric intervention has been introduced on the other hand.

In conclusion, our study found no difference in plasma FGF23 levels between hypercalciuric and control children. Pharmacologically treated patients had significantly lower urine calcium excretion rate, lower plasma FGF23 levels, and elevated TP/GFR and serum phosphate without significant changes in serum PTH values. It thus seems that the reversal of hypercalciuria may directly or indirectly affect phosphate metabolism. We recommend that future studies will differentiate between Treated and Pre-Treated patients and will include 1,25(OH)_{2}D_{3} amongst all other measured variables.

Acknowledgments

The authors thank Nancy J. Wilson for her valuable technical laboratory assistance and personal support, Sylvia Dimaggio and Christopher McNown for technical assistance, Ashley Herman for statistical support, Augusto C. S. Santos for samples collections, and Dr. João Milton Martins de Oliveira Penido for his valuable advice. This study was supported by the laboratories of Children’s Mercy Hospital and Clinics, Kansas City, MO, USA, and by the laboratories of the Clinics Hospital of the Federal University of Minas Gerais, Belo Horizonte, Brazil.

References

[1] M. G. M. G. Penido, T. Srivastava, and U. S. Alon, “Pediatric primary urolithiasis: 12-year experience at a midwestern children’s hospital,” The Journal of Urology, vol. 189, no. 4, pp. 1493–1497, 2013.

[2] M. G. M. G. Penido, E. M. Lima, V. S. P. Marino, A. L. F. Tupinambá, A. França, and M. F. O. Souto, “Bone alterations in children with idiopathic hypercalciuria at the time of diagnosis,” Pediatric Nephrology, vol. 18, no. 2, pp. 133–139, 2003.

[3] S. Skalova, V. Palicka, and S. Kutilek, “Bone mineral density and urinary N-acetyl-𝛽-D-glucosaminidase activity in paediatric patients with idiopathic hypercalciuria,” Nephrology, vol. 10, no. 2, pp. 99–102, 2005.

[4] J. R. Asplin, S. Donahue, J. Kinder, and F. L. Coe, “Urinary calcium excretion predicts bone loss in idiopathic hypercalciuria,” Kidney International, vol. 70, no. 8, pp. 1463–1467, 2006.

[5] E. M. Worcester and F. L. Coe, “New insights into the pathogenesis of idiopathic hypercalcemia,” Seminars in Nephrology, vol. 28, no. 2, pp. 120–132, 2008.

[6] K. Sakhaee, N. M. Maalouf, R. Kumar, A. Pasch, and O. W. Moe, “Nephrolithiasis-associated bone disease: pathogenesis and treatment options,” Kidney International, vol. 79, no. 4, pp. 393–403, 2011.

[7] A. V. Osorio and U. S. Alon, “The relationship between urinary calcium, sodium, and potassium excretion and the role of potassium in treating idiopathic hypercalciuria,” Pediatrics, vol. 100, no. 4, pp. 675–681, 1997.

[8] U. S. Alon and A. Benrebom, “Idiopathic hypercalciuria of childhood: 4- to 11-year outcome,” Pediatric Nephrology, vol. 14, no. 10–11, pp. 1011–1015, 2000.

[9] U. S. Alon, H. Zimmerman, and M. Alon, “Evaluation and treatment of pediatric idiopathic urolithiasis - Revisited,” Pediatric Nephrology, vol. 19, no. 5, pp. 516–520, 2004.

[10] D. Telci, A. U. Dogan, E. Ozbek et al., “KLOTHO gene polymorphism of G395A is associated with kidney stones,” American Journal of Nephrology, vol. 33, no. 4, pp. 337–343, 2011.

[11] E. M. Worcester and F. L. Coe, “Evidence for altered renal tubule function in idiopathic calcium stone formers,” Urolithiasis, vol. 38, no. 4, pp. 263–269, 2010.

[12] D. Prič, V. Ravery, L. Boccon-Gibod, and G. Friedlander, “Frequency of renal phosphate leak among patients with calcium nephrolithiasis,” Kidney International, vol. 60, no. 1, pp. 272–276, 2001.

[13] D. Rendina, G. Mossetti, G. De Filippo, M. Cioffi, and P. Strazzullo, “Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 3, pp. 959–963, 2006.
[14] E. N. Taylor, A. N. Hoofnagle, and G. C. Curhan, “Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones,” *Clinical Journal of the American Society of Nephrology*, vol. 10, no. 4, pp. 667–675, 2015.

[15] V. Barcellos Menon, R. M. Affonso Moysés, S. A. Gomes, A. B. De Carvalho, V. Jorgetti, and I. Pfeferman Heilberg, “Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers,” *Clinical Journal of the American Society of Nephrology*, vol. 9, no. 7, pp. 1263–1270, 2014.

[16] T. Srivastava and A. Schwaderer, “Diagnosis and management of hypercalciuria in children,” *Current Opinion in Pediatrics*, vol. 21, no. 2, pp. 214–219, 2009.

[17] S. Hellerstein, S. D. Simon, M. Berenbom, P. Erwin, and E. Nickell, “Creatinine excretion rates for renal clearance studies,” *Pediatric Nephrology*, vol. 16, no. 8, pp. 637–643, 2001.

[18] M. G. M. G. Penido and U. S. Alon, “Phosphate homeostasis and its role in bone health,” *Pediatric Nephrology*, vol. 27, no. 11, pp. 2039–2048, 2012.

[19] M. G. M. G. Penido and U. S. Alon, “Hypophosphatemic rickets due to perturbations in renal tubular function,” *Pediatric Nephrology*, vol. 29, no. 3, pp. 361–373, 2014.

[20] M. J. Favus, A. J. Karnauskas, J. H. Parks, and F. L. Coe, “Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 89, no. 10, pp. 4937–4943, 2004.

[21] F. L. Coe, J. H. Parks, A. Evan, and E. Worcester, “Pathogenesis and treatment of nephrolithiasis,” *Seldin and Giebisch’s The Kidney*, pp. 1945–1977, 2008.

[22] J. E. Zerwekh, B. Y. Reed, H. J. Heller, G. B. González, M. R. Haussler, and C. Y. C. Pak, “Normal vitamin D receptor concentration and responsiveness to 1,25-dihydroxyvitamin D3 in skin fibroblasts from patients with absorptive hypercalciuria,” *Mineral and Electrolyte Metabolism*, vol. 24, no. 5, pp. 307–313, 1998.

[23] N. D. Adams, R. W. Gray, J. Lemann Jr., and H. S. Cheung, “Effects of calcitriol administration on calcium metabolism in healthy men,” *Kidney International*, vol. 21, no. 1, pp. 90–97, 1982.

[24] W. J. Maierhofer, R. W. Gray, H. S. Cheung, and J. Lemann Jr., “Bone resorption stimulated by elevated serum 1,25-(OH)2vitamin D concentrations in healthy men,” *Kidney International*, vol. 24, no. 4, pp. 555–560, 1983.

[25] C. D. Scales, G. E. Tasian, A. L. Schwaderer, D. S. Goldfarb, R. A. Star, and Z. Kirkali, “Urinary stone disease: advancing knowledge, patient care, and population health,” *Clinical Journal of the American Society of Nephrology*, vol. 11, no. 7, pp. 1305–1312, 2016.

[26] E. N. Taylor, T. T. Fung, and G. C. Curhan, “DASH-style diet associates with reduced risk for kidney stones,” *Journal of the American Society of Nephrology*, vol. 20, no. 10, pp. 2253–2259, 2009.

[27] Q. Chang, S. Hoefs, A. W. Van Der Kemp, C. N. Topala, R. J. Bindels, and J. G. Hoenderop, “The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel,” *Science*, vol. 310, no. 5747, pp. 490–493, 2005.
